The purpose of this study is to evaluate the efficacy and safety of Atorvastatin and Fenofibrate compared with atorvastatin monotherapy in mixed hypercholesterolemic patients.

Multi center, randomized, double-blind, parallel-group, therapeutic confirmatory study

Primary Outcome Measure:

The mean percent change of Non-HDL Cholesterol [Time Frame: from baseline at week 8]

Secondary Outcome Measures:

The achievement rate of LDL-C<100mg/dl, Non-HDL-C<130mg/dl [Time Frame: from baseline at week 8] The mean percent change of LDL-C, HDL-C, TG, TC, Apo-AI, Apo-B [Time Frame: from baseline at week 4, 8] The mean percent change of Non-LDL-C/HDL-C, TC/HDL-C, LDL-C/HDL-C, Apo-B/Apo-AI [Time Frame: from baseline at week 4, 8] The mean percent change of Fibrinogen, hs-CRP [Time Frame: from baseline at week 4, 8] Safety evaluation [Time Frame: Treatment period and Extension period]

Inclusion Criteria:

• >19 years old

• High risk patient to Coronary Heart Disease (applied to 1 or more CHD risk factor listed below)

  1. Patient with Coronary Heart Disease
  2. Patient with carotid artery disease, peripheral blood vessel disease, abdominal aneurysm
  3. Patient with diabetes(HbA1C≤9.0%)
  4. 10-year risk of CHD >20%(by Framingham 10-year risk score calculation)

• At Visit 1(Screening)

  1. 100mg/dl≥LDL-C, 150mg/dl≤TG≤500mg/dl

     • 4weeks of Atorvastatin 20mg monotherapy run-in period

  2. LDL-C<100mg/dl, 150mg/dl≤TG≤500mg/dl

     • If treated with Atorvastatin 20mg monotherapy 4weeks prior to this study

• At Visit 2(After 4weeks of Atorvastatin monotherapy run-in period)

  • LDL<100mg/dl, 150mg/dl≤TG≤500mg/dl

Exclusion Criteria:

• Patients with acute artery disease within 3 months
• Patients with congestive heart failure(NYHA class III~IV) or uncontrolled arrhythmia within 6 months
• Patients with uncontrolled hypertension(SBP>160mmHg or DBP>95mmHg)
• TSH>1.5X ULN
• Patients with myopathy, rhabdomyolysis or CK>2X ULN
• Hypersensitive to Atorvastatin and/or Fenofibrate or had photoallergy or phototoxicity during fibrate and/or ketoprofen treatment
• Serum Creatinine>2.5mg/dl, AST or ALT > 2X ULN
• History of drug or alcohol abuse within 6 months
• History of GI tract surgery or disability to drug absorption
• Women with pregnant, breast-feeding
• Patients with gallbladder disease
• Patients with biliary cirrhosis
• Patients with pancreatitis(acute pancreatitis is excluded due to severe hypertriglyceridemia)
• Patients treated with any investigational drugs within 4 weeks at the time consents are obtained
• History of malignant tumor including leukemia, lymphoma within 5 years
• Patients must be treated with medications prohibited for concomitant use during study period
• Not eligible to participate for the study at the discretion of investigator